Evidence map›Paper›PMID 28934281›Full record

ArticlePloS one2017

Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging.

Kevin Affram, Ofonime Udofot, Mandip Singh, Sunil Krishnan, Renee Reams, Jens Rosenberg, Edward Agyare

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Nanoparticles for Stem Cell Therapy Bioengineering in Glioma.Frontiers in bioengineering and biotechnology · 2020
    Review
  13. Article
  14. Clinical Trials of Thermosensitive Nanomaterials: An Overview.Nanomaterials (Basel, Switzerland) · 2019
    Review
  15. Article
  16. Review
  17. Florida-California Cancer Research, Education and Engagement (CaRECancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Kevin AfframCollege of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, Florida, United States of America.
Ofonime UdofotCollege of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, Florida, United States of America.
Mandip SinghCollege of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, Florida, United States of America.
Sunil KrishnanThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Renee ReamsCollege of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, Florida, United States of America.
Jens RosenbergThe National High Magnetic Field Laboratory, Florida State University, Tallahassee, Florida, United States of America.
Edward AgyareCollege of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, Florida, United States of America.ORCID http://orcid.org/0000-0002-6905-5136
Florida Agricultural and Mechanical University · USFlorida State University · USThe University of Texas MD Anderson Cancer Center · US

Funding

Research Project-3: Effectiveness of an eHealth intervention for uptake of cervical cancer screening in Hispanic womenU54MD007582 · NIMHD · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI Seth Y Ablordeppey · 2019 to 2026
$28.1M
Recruitment and HiringG12MD007582 · NIMHD · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI SOLIMAN, KARAM F.A. · 2012 to 2017
$16.0M
Florida Minority Cancer Research & Training Center: Feasibility Studies (1 of 2)P20CA192990 · NCI · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · PI REAMS, ROMONIA RENEE · 2014 to 2017
$686k
NCI NIH HHS P20 CA192990NIMHD NIH HHS G12 MD007582NIMHD NIH HHS U54 MD007582
6 · The paper itself

Abstract

In numerous studies, liposomes have been used to deliver anticancer drugs such as doxorubicin to local heat-triggered tumor. Here, we investigate: (i) the ability of thermosensitive liposomal nanoparticle (TSLnp) as a delivery system to deliver poorly membrane-permeable anticancer drug, gemcitabine (Gem) to solid pancreatic tumor with the aid of local mild hyperthermia and, (ii) the possibility of using gadolinium (Magnevist®) loaded-TSLnps (Gd-TSLnps) to increase magnetic resonance imaging (MRI) contrast in solid tumor. In this study, we developed and tested gemcitabine-loaded thermosensitive liposomal nanoparticles (Gem-TSLnps) and gadolinium-loaded thermosensitive liposomal nanoparticles (Gd-TSLnps) both in in-vitro and in-vivo. The TSLnps exhibited temperature-dependent release of Gem, at 40-42°C, 65% of Gem was released within 10 min, whereas < 23% Gem leakage occurred at 37°C after a period of 2 h. The pharmacokinetic parameters and tissue distribution of both Gem-TSLnps and Gd-TSLnps were significantly greater compared with free Gem and Gd, while Gem-TSLnps plasma clearance was reduced by 17-fold and that of Gd-TSLpns was decreased by 2-fold. Area under the plasma concentration time curve (AUC) of Gem-TSLnps (35.17± 0.04 μghr/mL) was significantly higher than that of free Gem (2.09 ± 0.01 μghr/mL) whereas, AUC of Gd-TSLnps was higher than free Gd by 3.9 fold high. TSLnps showed significant Gem accumulation in heated tumor relative to free Gem. Similar trend of increased Gd-TSLnps accumulation was observed in non-heated tumor compared to that of free Gd; however, no significant difference in MRI contrast enhancement between free Gd and Gd-TSLnps ex-vivo tumor images was observed. Despite Gem-TSLnps dose being half of free Gem dose, antitumor efficacy of Gem-TSLnps was comparable to that of free Gem(Gem-TSLnps 10 mg Gem/kg compared with free Gem 20 mg/kg). Overall, the findings suggest that TSLnps may be used to improve Gem delivery and enhance its antitumor activity. However, the formulation of Gd-TSLnp needs to be fully optimized to significantly enhance MRI contrast in tumor.

Indexed as

Contrast MediaLiposomesMagnetic Resonance ImagingAnimalsAntineoplastic AgentsArea Under CurveCell Line, TumorDeoxycytidineDrug Delivery SystemsDrug LiberationFemaleGadoliniumGemcitabineHot TemperatureMice, NudeModels, BiologicalAntineoplastic AgentsContrast MediaDeoxycytidineGadoliniumGemcitabineLiposomes

Identifiers

PMID28934281
PMCPMC5608370
OpenAlexW2757645865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.